NEW YORK (GenomeWeb News) – Prometheus Laboratories has licensed US rights to Rosetta Genomics' recently introduced microRNA-based tests and has taken an equity stake in the molecular diagnostics firm.

San Diego-based Prometheus has gained the right to sell the miRview mets, miRview squamous, and miRview meso, which Rosetta launched in late 2008. It will provide Rosetta with payments, either in the form of milestones or R&D funding, and royalties based on net sales in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.